title: [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
abstract: In order to assess the mortality and toxicity of the Hyper-CVAD protocol used as first-line treatment of acute lymphoblastic leukemia, a retrospective cohort study was performed in patients less than 40 years of age from March to September 2011 treated with Hyper-CVAD regimen. Mortality and toxicity was compared with the results of patients treated with the institutional HGMLAL07 regimen between 2009-2012. 18 patients were included; the median age was 26 years old. Complete remissions (67.7% versus 81.9%) as well as one-year (40% versus 62%) and 2 year survival rates (18% versus 34%) were lower with the Hyper-CVAD regimen. By selecting only patients younger than 35 years, the effectiveness of Hyper-CVAD was also lower. In our experience and because of its high cost and toxicity, the Hyper-CVAD regimen should be limited to patients with relapsed or refractory leukemia.
authors.affiliation: Hospital General de México, México.
authors.forename: Christian Omar
authors.initials: CO
authors.lastname: Ramos-Peñafiel
authors.affiliation: Hospital General de México, México.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Cabrera-García
authors.affiliation: Hospital General de México, México.
authors.forename: Etta
authors.initials: E
authors.lastname: Rozen-Fuller
authors.affiliation: Hospital General de México, México.
authors.forename: Guadalupe
authors.initials: G
authors.lastname: González-León
authors.affiliation: Hospital General de México, México.
authors.forename: Carolina
authors.initials: C
authors.lastname: Balderas
authors.affiliation: Hospital General de México, México.
authors.forename: Juan Julio
authors.initials: JJ
authors.lastname: Kassack-Ipiña
authors.affiliation: Hospital General de México, México.
authors.forename: Humberto
authors.initials: H
authors.lastname: Castellanos-Sinco
authors.affiliation: Hospital General de México, México.
authors.forename: Carlos
authors.initials: C
authors.lastname: Martínez-Murillo
authors.affiliation: Hospital General de México, México.
authors.forename: Efreen
authors.initials: E
authors.lastname: Montaño-Figueroa
authors.affiliation: Hospital General de México, México.
authors.forename: Adolfo
authors.initials: A
authors.lastname: Martínez-Tovar
authors.affiliation: Hospital General de México, México.
authors.forename: Irma
authors.initials: I
authors.lastname: Olarte-Carrillo
authors.affiliation: Facultad de Medicina, Universidad Nacional Autónoma de México, México.
authors.forename: Adrián
authors.initials: A
authors.lastname: Santoyo-Sánchez
authors.affiliation: Hospital General de México, México.
authors.forename: Juan
authors.initials: J
authors.lastname: Collazo-Jaloma
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006761:Hospitals; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide